Aprogen Pharmaceuticals Inc Total Liabilities
Aprogen Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has total liabilities worth ₩288.27 Billion KRW (≈ $195.35 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aprogen Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aprogen Pharmaceuticals Inc (2009–2024)
Total liabilities of Aprogen Pharmaceuticals Inc from 2009 to 2024. This chart illustrates how Aprogen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Aprogen Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Aprogen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
USA | $727.22 Million |
|
Shin Ruenn Development Co Ltd
TWO:6186
|
Taiwan | NT$12.22 Billion |
|
Patriot Acquisition Corp.
NASDAQ:PTAC
|
USA | $7.88 Million |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
Spain | €78.36 Million |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
Indonesia | Rp1.61 Billion |
|
Datawalk SA
WAR:DAT
|
Poland | zł105.76 Million |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
France | €11.62 Billion |
|
Thrace Plastics Holding and Commercial S.A
AT:PLAT
|
Greece | €171.85 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Aprogen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Aprogen Pharmaceuticals Inc balance sheet assets.
Liquidity & Leverage Metrics
Aprogen Pharmaceuticals Inc Total Liabilities Ratios Explained
Aprogen Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aprogen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual total liabilities of Aprogen Pharmaceuticals Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩212.29 Billion ≈ $143.87 Million |
-3.81% |
| 2023-12-31 | ₩220.71 Billion ≈ $149.57 Million |
+27.04% |
| 2022-12-31 | ₩173.73 Billion ≈ $117.73 Million |
+896.14% |
| 2021-12-31 | ₩17.44 Billion ≈ $11.82 Million |
+2.87% |
| 2020-12-31 | ₩16.95 Billion ≈ $11.49 Million |
-3.93% |
| 2019-12-31 | ₩17.65 Billion ≈ $11.96 Million |
-73.49% |
| 2018-12-31 | ₩66.55 Billion ≈ $45.10 Million |
-17.24% |
| 2017-12-31 | ₩80.41 Billion ≈ $54.49 Million |
+59.01% |
| 2016-12-31 | ₩50.57 Billion ≈ $34.27 Million |
+189.37% |
| 2015-12-31 | ₩17.48 Billion ≈ $11.84 Million |
-23.06% |
| 2014-12-31 | ₩22.71 Billion ≈ $15.39 Million |
+4.62% |
| 2013-12-31 | ₩21.71 Billion ≈ $14.71 Million |
-11.65% |
| 2012-12-31 | ₩24.58 Billion ≈ $16.65 Million |
-42.64% |
| 2011-12-31 | ₩42.85 Billion ≈ $29.04 Million |
+19.37% |
| 2010-12-31 | ₩35.89 Billion ≈ $24.32 Million |
+36.66% |
| 2010-09-30 | ₩26.26 Billion ≈ $17.80 Million |
-22.50% |
| 2009-12-31 | ₩33.89 Billion ≈ $22.97 Million |
-- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.